Search

The Pharma Letter
The Pharma Letter @ThePharmaLetter ·
Three strikes. Aldeyra's shares have plunged after a third consecutive FDA rejection for reproxalap. At what point does persistence become a liability to shareholders? #FDA #biotech #drugdevelopment #clinicaltrials thepharmaletter.com/pharma-news/al…
Aldeyra shares plunge after third FDA rejection for reproxalap

US biotech Aldeyra Therapeutics (Nasdaq: ALDX) has received a third complete response letter from the American medicines regulator for its dry eye candidate reproxalap, sending shares down around 68%.

From thepharmaletter.com
82
biotech
biotech @Avocadosssss ·
Novartis to acquire Excellergy for up to $2B for its Xolair successor drug, aiming for faster allergic condition control. #biopharma #drugdevelopment #allergy $NVS $RHHBY biopharmadive.com/news/novartis-…
Novartis targets Xolair successor in buyout of startup Excellergy

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.

From biopharmadive.com
61
Cytonics Corp
Cytonics Corp @CytonicsCorp ·
Risk Down. Upside Expanding. Phase 1 complete. Safety established. Phase 2 underway. This is where biotech shifts from uncertainty to evidence. As risk comes down, opportunity expands. Real data. Real momentum. #biotech #clinicaltrials #drugdevelopment #biotechinvesting REG g an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Cytonics has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: rb.gy/24a8ut
3
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News @GENbio ·
Xaira's First Virtual Cell Model Is Largest To-Date, Toward Complex Biology X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain @Xaira_Thera #virtualcell #AI #drugdevelopment hubs.li/Q048tMk50
Xaira's First Virtual Cell Model Is Largest To-Date, Toward Complex Biology

X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.

From genengnews.com
5
516